Trial Profile
High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy lesions in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 26 Feb 2016 New trial record